Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acebilustat - Celtaxsys

Drug Profile

Acebilustat - Celtaxsys

Alternative Names: CTX-4430; EP-501

Latest Information Update: 12 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Celtaxsys; Stanford University
  • Class Anti-inflammatories; Antiacnes; Antifibrotics; Antihypertensives; Antivirals; Skin disorder therapies; Small molecules
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Cystic fibrosis; Lymphoedema
  • No development reported Bronchiectasis; Pulmonary hypertension; Skin disorders
  • Discontinued Acne vulgaris; Hidradenitis suppurativa; Rosacea

Most Recent Events

  • 19 May 2023 Efficacy and adverse event data from phase II trial in COVID-19 infections presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 02 Feb 2023 Stanford University completes the phase II trial for COVID-2019 infections (In adults; In the elderly; Combination therapy) in UK (PO, Capsule) (NCT04662086)
  • 27 Jul 2022 Phase-II clinical trials in Lymphoedema in USA (PO) (NCT05203835)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top